Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CNS

Set Alert for CNS

Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus

The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.

Companies Business Strategies

Five Pivotal Trial Read-Outs To Look Out For In Early 2022

Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.

Clinical Trials Companies

J.P. Morgan Day 4: Preparing For The Year Ahead

Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem, Hanmi and Fosun; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases. 

Companies Deals

Could Aduhelm Be Taken Off Market If CMS Proposal Stands? ‘Everything Is On The Table,’ Biogen Says

Company execs say there has been four-fold increase in doctors infusing the Alzheimer’s drug and despite lack of support from major institutions, individual physicians at Cleveland Clinic and elsewhere have voiced support for Aduhelm. Biogen is “cautiously optimistic” about lecanemab Phase III trial.

Medicare Reimbursement

ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands

ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.

Deals Neurology

Idorsia Adds Hollywood Sparkle To Sleep Drug Quviviq

The Swiss biotech needs to wait for a scheduling review before it can officially launch the insomnia drug Quviviq but this delay gives Idorsia a few months to prime the US market with educational campaigns.

Launches Business Strategies

Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

Reimbursement Market Access

Idorsia In Dreamland With Insomnia Drug Approval

The Swiss biotech has got the thumbs up in the US for its insomnia drug which will be sold as Quviviq and is expected to be provide serious competition for Merck & Co's rival dual orexin receptor antagonist Belsomra.

Approvals Neurology

Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge

The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.

Generic Drugs Neurology

Ovid Starts Neurology Spree With AstraZeneca Deal

The company is using proceeds from last year’s handover of its lead epilepsy program to Takeda to fuel a push in neurology development.

Neurology Business Strategies

Stock Watch: Bridgebio’s Endpoint A Bridge Too Far

The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.

Stock Watch Research & Development

New Body Blow For Aducanumab As Japan Asks For More Data

Request for additional data after a surprise review committee meeting sets back approval in potentially large market, adding to Biogen and Eisai’s woes following the recent EU negative opinion and poor performance and price cut in the US.

Japan Neurology
See All
UsernamePublicRestriction

Register